BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

STB Lifesaving Technologies: Successful Pre-IND FDA Filing for STB's FAST(R) Dressing Propels Lifesaving Technology Forward


10/18/2010 9:13:03 AM

ROCKVILLE, Md., Oct. 18 /PRNewswire/ -- STB Lifesaving Technologies® today announced that is has completed a successful pre-Investigational New Drug (pre-IND) submission to the U.S. Food and Drug Administration (FDA) for its lead product, the Fibrin Adhesive STat®, or (FAST®) dressing.

STB® has conducted successful animal studies for the FAST® dressing with both military and commercial partners and is further supported by published data from the American Red Cross. In these published comparative animal studies, Fibrin Adhesive STat®, or (FAST®) dressing has proven to be functionally superior in significantly reducing blood loss. The FAST® dressing contains large quantities of the human blood clotting proteins fibrinogen, thrombin, and Factor XIII in a dry form. Once in contact with the wound, the components in the FAST® dressing are instantly activated to form a fibrin clot similar to that which results from the body's own clotting process.

"The FDA provided us with some very helpful and substantive comments," said Richard Moscarello, CEO of STB®. "We have incorporated them and now are finalizing our development plan and partner relationships, so we can go forward with our IND filing as soon as possible. This will a very significant milestone in the strategic plan we've set for STB®, and will allow us to penetrate the multi-billion dollar hemostatic market and begin saving lives." The Company has the remaining pre-IND development work and animal studies for the FAST® dressing underway.

STB Lifesaving Technologies® is a biotechnology company that is developing a comprehensive suite of products to stop serious and life threatening bleeding in trauma and surgical settings. Its flagship product, Fibrin Adhesive STat (FAST®) dressing, is designed to be effective against the full spectrum of blood loss, including severe arterial and venous bleeding.

SOURCE STB Lifesaving Technologies



Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES